Search

Your search keyword '"Enbrel (Medication) -- Evaluation"' showing total 41 results
Start Over Descriptor "Enbrel (Medication) -- Evaluation"
41 results on '"Enbrel (Medication) -- Evaluation"'

1. Immunologic targets in psoriasis

Author

Kupper, Thomas S.

Subjects
Genentech Inc. -- Product information, Immunex Corp. -- Product information, Raptiva (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation, Biological products industry -- Product information, Psoriasis -- Drug therapy
Abstract

The drugs Raptiva and Enbrel represent a new way of treating a skin disease called psoriasis. Both drugs affect the immune system because psoriasis is a type of autoimmune disease in which the immune system attacks the body. They may be effective in treating patients with severe psoriasis, according to two studies published in 2003.

Published
2003

2. Etanercept as monotherapy in patients with psoriasis

Author

Leonardi, Craig L., Powers, Jerold L., Matheson, Robert T., Goffe, Bernard S., Zitnik, Ralph, Wang, Andrea, and Gottlieb, Alice B.

Subjects
Immunex Corp. -- Product information, Enbrel (Medication) -- Evaluation, Pharmaceutical industry -- Product information, Psoriasis -- Drug therapy
Abstract

The drug Enbrel may be effective in treating severe psoriasis, according to a study of 652 patients. The drug was given as a subcutaneous injection once a week for up to six months. Between 25% and 59% of the patients had a 75% or greater improvement in symptoms, depending on the dose. Enbrel blocks the activity of tumor necrosis factor, which is believed to cause some of the symptoms of psoriasis.

Published
2003

3. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

Author

Gorman, Jennifer D., Sack, Kenneth E., and Davis, John C., Jr.

Subjects
Immunex Corp. -- Product information, Enbrel (Medication) -- Evaluation, Pharmaceutical industry -- Product information, Ankylosing spondylitis -- Drug therapy
Abstract

The drug Enbrel may be effective for treating a spinal disease called ankylosing spondylitis, according to a study of 40 patients. This drug blocks the activity of tumor necrosis factor alpha, which is produced in greater than normal amounts in patients with arthritis.

Published
2002

4. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

Author

Bathon, Joan M., Martin, Richard W., Fleischmann, Roy M., Tesser, John R., Schiff, Michael H., Keystone, Edward C., Genovese, Mark C., Wasko, Mary Chester, Moreland, Larry W., Weaver, Arthur L., Markenson, Joseph, and Finck, Barbara K.

Subjects
Enbrel (Medication) -- Evaluation, Rheumatoid arthritis -- Drug therapy, Methotrexate -- Evaluation
Abstract

Subcutaneous injections of etanercept may be more effective than methotrexate in relieving the symptoms of rheumatoid arthritis, according to a study of 632 people. Etanercept is a form of the tumor necrosis factor (TNF) receptor that blocks the activity of TNF.

Published
2000

5. Etanercept in children with polyarticular juvenile rheumatoid arthritis

Author

Lovell, Daniel J., Giannini, Edward H., Reiff, Andreas, Cawkwell, Gail D., Silverman, Earl D., Nocton, James J., Stein, Leonard D., Gedalia, Abraham, Ilowite, Norman T., Wallace, Carol A., Whitmore, James, and Finck, Barbara K.

Subjects
Enbrel (Medication) -- Evaluation, Rheumatoid arthritis in children -- Drug therapy
Abstract

The drug etanercept appears to be beneficial in children with juvenile rheumatoid arthritis. This drug blocks the activity of tumor necrosis factor, which is an inflammatory protein produced in the body. Researchers randomly assigned 51 children with juvenile rheumatoid arthritis to receive subcutaneous injections of etanercept or a placebo twice a week for up to four months. Over 80% of the children receiving etanercept improved, compared to 28% of those receiving a placebo. The drug had minimal side effects. Etanercept is sold under the trade name Enbrel.

Published
2000

6. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, patients with rheumatoid arthritis receiving methotrexate

Author

Weinblatt, Michael E., Kremer, Joel M., Bankhurst, Arthur D., Bulpitt, Ken J., Fleischmann, Roy M., Fox, Robert I., Jackson, Christopher G., Lange, Mary, and Burge, Daniel J.

Subjects
Immunex Corp. -- Product information, Enbrel (Medication) -- Evaluation, Rheumatoid arthritis -- Drug therapy, Methotrexate -- Evaluation
Abstract

Etanercept in addition to methotrexate may be more effective than methotrexate alone in treating rheumatoid arthritis. Etanercept is a drug that inhibits the action of tumor necrosis factor, which causes inflammation. Researchers randomly assigned 89 rheumatoid arthritis patients to take methotrexate alone or methotrexate and etanercept. After six months of treatment, 71% of the patients taking both drugs experienced a 20% improvement in function and 39% experienced a 50% improvement. The percentages of people taking methotrexate alone who achieved these results were 27% and 3%, respectively.

Published
1999

7. Fitch Rates Pfizer's Exchange Notes Offering 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Securities offerings, Pharmaceutical industry -- Forecasts and trends -- Securities, Arts and entertainment industries, Enbrel (Medication) -- Evaluation
Abstract

The following is from Fitch Ratings on September 8: Fitch Ratings has assigned an 'A+' to Pfizer Inc.'s (Pfizer's) senior unsecured notes offering, which will be used to exchange Hospira's [...]

Published
2015

8. Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Arts and entertainment industries, Enbrel (Medication) -- Evaluation
Abstract

The following is from Fitch Ratings on September 26: Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating actions apply to approximately [...]

Published
2014

9. Fitch Affirms Amgen's IDR at 'BBB'; Ratings Outlook Stable

Subjects
Amgen Inc. -- Securities, Biotechnology industry -- Securities, Company securities, Arts and entertainment industries, Enbrel (Medication) -- Evaluation
Abstract

Fitch Ratings has affirmed Amgen Inc.'s (Amgen) ratings, including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings affirmed is listed below. [...]

Published
2013

11. Event Brief of Q1 2014 Amgen Earnings Conference Call - Final

Subjects
Amgen Inc., Barclays Capital Inc., Investment banks -- Evaluation, Biotechnology industry, Business, Enbrel (Medication) -- Evaluation, Neupogen (Medication) -- Evaluation
Abstract

CORPORATE PARTICIPANTS . Arvind Sood - Amgen Inc.,VP of IR . Bob Bradway - Amgen Inc.,Chairman & CEO . Michael Kelly - Amgen Inc.,Interim CFO . Tony Hooper - Amgen [...]

Published
2014

12. Etanercept efficacy for psoriatic arthritis sustained at 2 years

Subjects
Enbrel (Medication) -- Evaluation, Psoriasis -- Care and treatment, Psoriatic arthritis -- Care and treatment, Etanercept -- Evaluation, Pharmaceuticals and cosmetics industries, Evaluation, Care and treatment
Abstract

Etanercept (Enbrel, Amgen /Wyeth) is effective for treating signs and symptoms of psoriatic arthritis and psoriasis for up to 106 weeks and also remains well-tolerated, researchers reported at the American [...]

Published
2004

13. Fitch Rates Pfizer's Notes Offering 'A+(exp)'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Fitch Ratings Ltd. -- Forecasts and trends -- Securities, Financial statements, Securities offerings, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has assigned an 'A+(EXP)' rating to Pfizer's senior unsecured notes offering. The net proceeds of the issuance will be used to fund the purchase of the [...]

Published
2016

14. Fitch Rates Pfizer's Notes Offering 'A+'

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Securities offerings, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has assigned an 'A+' rating to Pfizer's senior unsecured notes offering. Pfizer may use the net proceeds for general corporate purposes, including repaying a portion of [...]

Published
2016

15. Fitch Affirms Pfizer's IDR at 'A+'; Rating Outlook Stable

Subjects
Allergan PLC -- Forecasts and trends -- Securities, Pfizer Inc. -- Forecasts and trends -- Securities, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

NEW YORK -- Fitch Ratings has affirmed Pfizer's Long-Term Issuer-Default Rating (IDR) at 'A+' with a Stable Rating Outlook, removing the ratings form Negative Watch. The rating action follows Pfizer, [...]

Published
2016

16. PFIZER INC (PFE) Earnings Report: Q4 2015 Conference Call Transcript

Subjects
Merck KGaA, The Goldman Sachs Group Inc., Pfizer Inc., Bank of America Corp., Investment banks -- Evaluation, Banking industry, Antirheumatic agents -- Evaluation, Cancer -- Care and treatment, Pharmaceutical industry, Banking industry, Business, Xeljanz (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation, Sutent (Medication) -- Evaluation, Ibrance (Medication) -- Evaluation, Prevnar 13 (Vaccine) -- Evaluation
Abstract

Byline: TheStreet Transcripts To view this article on the web, click here: http://www.thestreet.com/story/13445494/1/pfizer-inc-pfe-earnings-report-q4-2015-conference-call-transcript.html The following PFIZER INC (PFE) conference call took place on February 2, 2016, 10:00 AM ET. This [...]

Published
2016

17. Arthritis Sufferers Get A New Option

Subjects
Rheumatoid arthritis -- Drug therapy, Health, Enbrel (Medication) -- Evaluation
Abstract

Etanercept (Enbrel) promises to offer a different kind of pain relief to patients with rheumatoid arthritis. Unlike aspirin and other traditional analgesics, the drug works directly on the immune system [...]

Published
1999

18. Q2 2008 Amgen Earnings Conference Call - Final

Subjects
Amgen Inc., Pharmaceutical industry, Business, Aranesp (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation
Abstract

Original Source: FD (FAIR DISCLOSURE) WIRE OPERATOR: My name is Dennis, and I will be your conference facilitator today for Amgen's second quarter 2008 financial results conference call. All lines [...]

Published
2008

19. Event Brief of Q1 2007 Wyeth Earnings Conference Call - Final

Subjects
Pharmaceutical industry, Business, Enbrel (Medication) -- Evaluation, Prevnar (Vaccine) -- Evaluation
Abstract

Original Source: FD (FAIR DISCLOSURE) WIRE PARTICIPANTS . Bob Essner, Wyeth, Chairman, CEO . Ken Martin, Wyeth, CFO, Vice Chairman . Bernard Poussot, Wyeth, President, Vice Chairman . Joe Mahady, [...]

Published
2007

20. Event Brief of Q1 2007 Wyeth Earnings Conference Call - Final

Subjects
The Goldman Sachs Group Inc., Investment banks -- Evaluation, Pharmaceutical industry, Business, Enbrel (Medication) -- Evaluation, Prevnar (Vaccine) -- Evaluation
Abstract

Original Source: FD (FAIR DISCLOSURE) WIRE PARTICIPANTS . Robert Essner, Wyeth, Chairman, CEO . Ken Martin, Wyeth, CFO, Vice Chairman . Bernard Poussot, Wyeth, President, Vice Chairman . Joe Mahady, [...]

Published
2007

21. Fitch Places Pfizer's L-T Ratings on Negative Watch Following Allergan Merger Announcement

Subjects
Allergan PLC -- Securities, Pfizer Inc. -- Securities, Pharmaceutical industry -- Securities, Company securities, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has placed Pfizer's long-term credit ratings on Negative Watch. The rating action follows Pfizer, Inc.'s (PFE) announcement that it will merge with Allergan plc (AGN) for [...]

Published
2015

22. Fitch Rates Pfizer's Exchange Notes Offering 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Securities offerings, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has assigned an 'A+' to Pfizer Inc.'s (Pfizer's) senior unsecured notes offering, which will be used to exchange Hospira's 2017, 2020, 2023 and 2040 senior unsecured [...]

Published
2015

23. Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends, Hospira Inc. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating action follows Pfizer's announcement that it will acquire Hospira, Inc. (HSP) [...]

Published
2015

24. Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating actions apply to approximately $37.8 billion of consolidated debt outstanding as [...]

Published
2014

25. Fitch Assigns an 'A+' Rating to Pfizer's Notes Offering

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, AstraZeneca PLC -- Forecasts and trends -- Securities, Securities offerings, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has assigned an 'A+' rating to Pfizer Inc.'s (Pfizer's) $4.5 billion notes offering. Fitch expects Pfizer to use the net proceeds for general corporate purposes, including [...]

Published
2014

26. New drugs better than expected

Author

Dunkin, Mary Anne

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Rheumatoid arthritis, Health, Enbrel (Medication) -- Evaluation, Remicade (Medication) -- Evaluation
Published
2001

27. Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

Subjects
Pfizer Inc. -- Forecasts and trends -- Securities, Pharmaceutical industry -- Forecasts and trends -- Securities, Company securities, Market trend/market analysis, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) Issuer Default Rating (IDR) at 'A+'. The rating actions apply to approximately $36.7 billion of consolidated debt outstanding as of June [...]

Published
2013

28. Fitch Affirms Amgen's IDR at 'BBB'; Ratings Outlook Stable

Subjects
Amgen Inc. -- Securities, Biotechnology industry -- Securities, Company securities, Business, Business, international, Enbrel (Medication) -- Evaluation
Abstract

CHICAGO -- Fitch Ratings has affirmed Amgen Inc.'s (Amgen) ratings, including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings affirmed is [...]

Published
2013

29. Biotech pipeline brims with promise; new drugs seem to enhance patients' survival chances following cardiac failure

Author

Anand, Geeta and Winslow, Ron

Subjects
Actelion Ltd. -- Product information, Genentech Inc. -- Product information, Scios Inc. -- Product information, Immunex Corp. -- Product information, Heart failure -- Care and treatment, Biotechnology industry -- Product information, Biological products industry -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Tezosentan (Medication) -- Evaluation, Bosentan (Medication) -- Evaluation, Natrecor (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation
Published
2001

30. FDA wants infection risk of Enbrel to be assessed

Subjects
United States. Food and Drug Administration -- Investigations, Immunex Corp. -- Product information, Pharmaceutical industry -- Product defects and recalls, Arthritis -- Drug therapy, Business, Business, general, Enbrel (Medication) -- Evaluation
Published
1999

31. Fitch Affirms Amgen's IDR at 'BBB'; Ratings Outlook Stable

Subjects
Amgen Inc. -- Securities, Biotechnology industry -- Securities, Company securities, Business, Business, international, Telecommunications industry, Enbrel (Medication) -- Evaluation
Abstract

Fitch Ratings has affirmed Amgen Inc.'s (Amgen) ratings, including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings affirmed is listed below. [...]

Published
2013

32. Psoriasis patients can have at-home care with new Tx: enbrel approved

Author

Splete, Heidi

Subjects
Enbrel (Medication) -- Evaluation, Psoriasis -- Drug therapy, Psoriasis -- Research
Abstract

Watch out, psoriasis, there's a "new" treatment in town--officially. The Food and Drug Administration has approved the biologic agent etanercept (Enbrel) for the treatment of chronic moderate to severe plaque [...]

Published
2004

33. New Relief for Psoriatic Arthritis

Author

Dunkin, Mary Anne

Subjects
Psoriatic arthritis -- Drug therapy, Psoriatic arthritis -- Care and treatment, Arthritis -- Care and treatment, Health, National Psoriasis Foundation -- Reports, Enbrel (Medication) -- Evaluation
Published
2002

34. New drug by Immunex approved for psoriatic arthritis. (Public Company News Briefs)

Subjects
United States. Food and Drug Administration -- Cases, Immunex Corp. -- Product information, American Home Products Corp. Wyeth-Ayerst Laboratories Div. -- Product information, Pharmaceutical industry -- Product information, Psoriatic arthritis -- Drug therapy, Business, Business, regional, Enbrel (Medication) -- Evaluation
Published
2002

35. New drugs in pipeline for dermatomyositis and IBM

Subjects
Dermatomyositis -- Drug therapy, Myositis -- Drug therapy, Consumer news and advice, Health, CellCept (Medication) -- Evaluation, Rituxan (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation, Avonex (Medication) -- Evaluation
Published
2001

36. UK DTB cautious on Enbrel/Remicade

Subjects
United Kingdom -- Health aspects, Wyeth -- Product information, Schering-Plough Corp. -- Product information, Novartis AG -- Product information, Medeva PLC -- Product information, Pharmacia Inc. -- Product information, Pharmaceutical industry -- Product information, Rheumatoid arthritis -- Drug therapy, Attention-deficit hyperactivity disorder -- Drug therapy, Antibiotics -- Evaluation, Gram-positive bacterial infections -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Enbrel (Medication) -- Evaluation, Remicade (Medication) -- Evaluation, Ritalin (Medication) -- Evaluation, Equasym (Medication) -- Evaluation, Dexedrine (Medication) -- Evaluation, Zyvox (Medication) -- Evaluation
Abstract

Information on the UK Drug and Therapeutics Bulletin's (DTB) evaluation of the therapeutic efficiency of Schering-Plough's Remicade and American Home Products' Enbrel in treating rheumatoid arthritis is offered. Additional information on DTB's evaluation of Novartis' Ritalin, Medeva's Dexedrine and Equasym - treatments for children's hyperactivity disorders and Pharmacia's Zyvox for treating Gram-positive infections is included.

Published
2001

37. More data on Enbrel required, says FDA panel

Subjects
United States. Food and Drug Administration -- Planning, Immunex Corp. -- Product information -- 00320281, Pharmaceutical industry -- Product information, Rheumatoid arthritis -- Drug therapy, Business, Pharmaceuticals and cosmetics industries, Enbrel (Medication) -- Evaluation
Published
1998

38. New FDA approvals

Subjects
AstraZeneca PLC -- Product information, GlaxoSmithKline Inc. (Research Triangle Park, North Carolina) -- Product information, Barr Laboratories Inc. -- Product information, Amgen Inc. -- Product information, Wyeth Pharmaceuticals Proprietary Ltd. -- Product information, Etanercept -- Usage, Etanercept -- Evaluation, Oral contraceptives -- Evaluation, Anti-impotence agents -- Evaluation, Pharmaceutical industry -- Product information, Anticholesteremic agents -- Evaluation, Statins -- Evaluation, Health care industry, Pharmaceuticals and cosmetics industries, Levitra (Medication) -- Evaluation, Enbrel (Medication) -- Evaluation
Abstract

These drugs recently received final approval from 31. the U.S. Food and Drug Administration (FDA): * Rosuvastatin (Crestor) by AstraZeneca. The FDA has approved rosuvastatin (Crestor), a statin in the [...]

Published
2003

39. New FDA approvals

Subjects
Otitis externa -- Care and treatment, Acute otitis media -- Care and treatment, Drugs -- Dosage and administration, Drugs -- Evaluation, Menopause -- Dosage and administration, Menopause -- Evaluation, Conjugated estrogens -- Evaluation, Conjugated estrogens -- Dosage and administration, Hemophilia -- Care and treatment, Blood coagulation factor VIII -- Evaluation, Blood coagulation factor VIII -- Usage, Barrett's esophagus -- Care and treatment, Antineoplastic agents -- Evaluation, Antineoplastic agents -- Usage, Antimitotic agents -- Evaluation, Antimitotic agents -- Usage, Stature, Short -- Care and treatment, Somatotropin -- Evaluation, Somatotropin -- Usage, Ankylosing spondylitis -- Care and treatment, Etanercept -- Evaluation, Etanercept -- Usage, Health care industry, Pharmaceuticals and cosmetics industries, Enbrel (Medication) -- Evaluation, Humatrope (Medication) -- Evaluation, Photofrin (Medication) -- Evaluation, PremPro (Medication) -- Evaluation
Abstract

These drugs recently received final approval from the U.S. Food and Drug Administration (FDA): * New indication for etanercept (Enbrel), which is manufactured by Immunex Corp. and marketed by Amgen [...]

Published
2003

40. Off-label drug use: etanercept (Enbrel) for Crohn's disease?

Author

Lowe, Angela Jezewski

Subjects
Inflammatory bowel diseases -- Drug therapy, Crohn's disease -- Drug therapy, Off-label prescribing -- Evaluation, Etanercept -- Evaluation, Health care industry, Pharmaceuticals and cosmetics industries, Enbrel (Medication) -- Evaluation
Abstract

Inflammatory bowel disease (IBD) has been clinically described for more than a century. Crohn's disease, one major type of IBD, has an incidence rate in the United States of approximately [...]

Published
2003

41. Psoriatic arthritis. (In the Pipeline)

Subjects
Immunex Corp. -- Product development, Psoriatic arthritis -- Drug therapy, Health care industry, Pharmaceuticals and cosmetics industries, Enbrel (Medication) -- Evaluation
Abstract

Immunex Corp. and Wyeth-Ayerst Laboratories have announced that the FDA granted 'priority review' status for Immunex's supplemental Biologics License Application to use etanercept (Enbrel) in the treatment of psoriatic arthritis. [...]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results